Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affetcs growth of B16-F10 tumors

• Autorzy: Mitrus I. , Sochanik A. , Cichon T. , Szala S.
• Języki publikacji: EN

Abstrakty

EN

The study aimed to check the effectiveness of anticancer therapy combining a vascular-disruptive drug (combretastatin phosphate, CA4P) and a liposomal formulation of a chemotherapeutic (doxorubicin). CA4P was synthesized in our laboratory according to a previously described procedure. The antivascular drug and long-circulating doxorubicin-loaded liposomes were used to treat B16-F10 murine melanoma experimental tumors. Seventy-four hours after drug administration, a decrease in the number of tumor blood vessels was apparent and necrotic areas within tumors were visible. Combination therapy consisting of alternate administrations of CA4P and liposomal doxorubicin yielded greater inhibition of tumor growth than monotherapies alone. The best therapeutic results were obtained with the antivascular drug administered intratumorally every second day at 50 mg/kg body mass. In the case of combined therapy, the best results were obtained when the vascular-disruptive agent (CA4P) and the antineoplastic agent (liposomal doxorubicin) were administered in alternation.

Słowa kluczowe

EN

doxorubicin; cancer therapy; liposome; combined therapy; effectiveness; combretastatin A4 phosphate

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2009
• Tom: 56
• Numer: 1
• Opis fizyczny: p.161-165,fig.,ref.

Twórcy

autor

Mitrus I.

• Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wybrzeze Armii Krajowej, 44-101 Gliwice, Poland

autor

Sochanik A.

autor

Cichon T.

autor

Szala S.

Bibliografia

• Bartlett GR (1958) Phosphorus assay in column chromatography. J Biol Chem 234: 466-468.
• Gabizon AA, Shmeeda H, Zalipsky S (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16: 175-183.
• Gaukroger K, Hadfield JA, Hepworth LA, Lawrence NJ, McGown AT (2001) Novel syntheses of cis and trans isomers of combretastatin A-4. J Org Chem 66: 8135-8138.
• Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539.
• Kanthou C, Tozer GM (2007) Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 11: 1443-1457.
• Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
• Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63: 7400-7409.
• Ribatti D, Nico B, Crivellato E, Vacca A (2007) The structure of the vascular network of tumors. Cancer Lett 248: 18-23.
• Salmon BA, Siemann DW (2007) Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 68: 211-217.
• Shi W, Horsman MR, Siemann DW (2006) Combined modality approaches using vasculature-disrupting agents. In Vascular-targeted Therapies in Oncology, Siemann DW, ed, pp 123-136. Chichester. John Wiley & Sons Ltd.
• Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6.
• Sivridis E, Giatromanolaki A, Koukourakis MI (2003) The vascular network of tumours — what is it not for? J Pathol 201: 173-180.
• Soloman R, Gabizon AA (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 8: 21-32.
• Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
• Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
• Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38.
• West CM, Price P (2004) Combretastatin A4 phosphate. Anticancer Drugs 15: 179-187.
• Zhou R, Mazurchuk R, Straubinger RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62: 2561-2566.